-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Talaris Therapeutics (NASDAQ:TALS) Shares Down 0.9%
Talaris Therapeutics (NASDAQ:TALS) Shares Down 0.9%
Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) shares were down 0.9% during mid-day trading on Monday . The stock traded as low as $1.08 and last traded at $1.10. Approximately 2,842 shares changed hands during trading, a decline of 98% from the average daily volume of 131,842 shares. The stock had previously closed at $1.11.
Wall Street Analyst Weigh In
A number of analysts recently commented on TALS shares. Morgan Stanley dropped their price target on Talaris Therapeutics from $8.00 to $6.00 and set an "equal weight" rating for the company in a research note on Friday, September 9th. HC Wainwright assumed coverage on Talaris Therapeutics in a research report on Thursday, October 20th. They issued a "buy" rating and a $18.00 target price for the company.
Get Talaris Therapeutics alerts:Talaris Therapeutics Stock Down 0.9 %
The firm has a fifty day moving average price of $1.47 and a two-hundred day moving average price of $3.24. The stock has a market capitalization of $45.90 million, a P/E ratio of -0.66 and a beta of 1.89.
Talaris Therapeutics (NASDAQ:TALS – Get Rating) last released its quarterly earnings data on Thursday, November 10th. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.04). Sell-side analysts anticipate that Talaris Therapeutics, Inc. will post -1.86 earnings per share for the current fiscal year.Hedge Funds Weigh In On Talaris Therapeutics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Values First Advisors Inc. increased its holdings in shares of Talaris Therapeutics by 163.0% in the 3rd quarter. Values First Advisors Inc. now owns 30,715 shares of the company's stock worth $81,000 after purchasing an additional 19,038 shares in the last quarter. BNP Paribas Arbitrage SNC bought a new stake in Talaris Therapeutics in the 3rd quarter worth about $64,000. Two Sigma Investments LP purchased a new position in Talaris Therapeutics in the 3rd quarter worth about $93,000. Bank of New York Mellon Corp lifted its stake in Talaris Therapeutics by 12.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 65,806 shares of the company's stock valued at $173,000 after acquiring an additional 7,112 shares during the period. Finally, Caas Capital Management LP purchased a new stake in shares of Talaris Therapeutics during the 3rd quarter valued at about $783,000. 65.43% of the stock is owned by institutional investors.
About Talaris Therapeutics
(Get Rating)
Talaris Therapeutics, Inc operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders.
Further Reading
- Get a free copy of the StockNews.com research report on Talaris Therapeutics (TALS)
- Three Healthcare Penny Stocks to Watch In The New Year
- Southwest Airlines Stock, There is a Lot to Love
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
Receive News & Ratings for Talaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) shares were down 0.9% during mid-day trading on Monday . The stock traded as low as $1.08 and last traded at $1.10. Approximately 2,842 shares changed hands during trading, a decline of 98% from the average daily volume of 131,842 shares. The stock had previously closed at $1.11.
塔拉里斯治疗公司(纳斯达克代码:TALS-GET Rating)股价周一午盘下跌0.9%。该股交易价格低至1.08美元,最后报1.10美元。约有2,842股股票在交易中易手,较131,842股的日均成交量下降了98%。该股此前收盘价为1.11美元。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
A number of analysts recently commented on TALS shares. Morgan Stanley dropped their price target on Talaris Therapeutics from $8.00 to $6.00 and set an "equal weight" rating for the company in a research note on Friday, September 9th. HC Wainwright assumed coverage on Talaris Therapeutics in a research report on Thursday, October 20th. They issued a "buy" rating and a $18.00 target price for the company.
一些分析师最近对Tals的股票发表了评论。9月9日,摩根士丹利将他们对Talaris治疗公司的目标价从8.00美元下调至6.00美元,并在一份研究报告中为该公司设定了“同等权重”的评级。在10月20日星期四的一份研究报告中,HC Wainwright承担了Talaris治疗公司的报道。他们对该公司的评级为“买入”,目标价为18.00美元。
Talaris Therapeutics Stock Down 0.9 %
Talaris治疗公司股价下跌0.9%
The firm has a fifty day moving average price of $1.47 and a two-hundred day moving average price of $3.24. The stock has a market capitalization of $45.90 million, a P/E ratio of -0.66 and a beta of 1.89.
该公司的50日移动均线价格为1.47美元,200日移动均线价格为3.24美元。该股市值为4,590万美元,市盈率为-0.66,贝塔系数为1.89。
Hedge Funds Weigh In On Talaris Therapeutics
对冲基金入股Talaris Treeutics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Values First Advisors Inc. increased its holdings in shares of Talaris Therapeutics by 163.0% in the 3rd quarter. Values First Advisors Inc. now owns 30,715 shares of the company's stock worth $81,000 after purchasing an additional 19,038 shares in the last quarter. BNP Paribas Arbitrage SNC bought a new stake in Talaris Therapeutics in the 3rd quarter worth about $64,000. Two Sigma Investments LP purchased a new position in Talaris Therapeutics in the 3rd quarter worth about $93,000. Bank of New York Mellon Corp lifted its stake in Talaris Therapeutics by 12.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 65,806 shares of the company's stock valued at $173,000 after acquiring an additional 7,112 shares during the period. Finally, Caas Capital Management LP purchased a new stake in shares of Talaris Therapeutics during the 3rd quarter valued at about $783,000. 65.43% of the stock is owned by institutional investors.
几家对冲基金和其他机构投资者最近增持或减持了该业务的股份。Values First Advisors Inc.在第三季度增持了163.0%的Talaris Treateutics股票。Values First Advisors Inc.现在持有30,715股该公司股票,价值81,000美元,该公司在上个季度又购买了19,038股。法国巴黎银行套利SNC在第三季度购买了Talaris Treeutics的新股份,价值约6.4万美元。Two Sigma Investments LP在第三季度购买了Talaris治疗公司的一个新头寸,价值约93,000美元。纽约梅隆银行(Bank Of New York Mellon Corp)在第三季度增持了Talaris治疗公司12.1%的股份。纽约梅隆银行(Bank Of New York Mellon Corp)目前持有65,806股该公司股票,价值173,000美元,在此期间又购买了7,112股。最后,CAAS Capital Management LP在第三季度购买了Talaris治疗公司的新股份,价值约783,000美元。65.43%的股份由机构投资者持有。
About Talaris Therapeutics
关于Talaris Treateutics
(Get Rating)
(获取评级)
Talaris Therapeutics, Inc operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders.
Talaris治疗公司在美国作为一家临床晚期细胞治疗公司运营。该公司致力于开发异基因造血干细胞移植的方法,以改变实体器官移植和严重的自身免疫性疾病以及严重的非恶性血液、免疫和代谢疾病的护理标准。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Talaris Therapeutics (TALS)
- Three Healthcare Penny Stocks to Watch In The New Year
- Southwest Airlines Stock, There is a Lot to Love
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
- 免费获取StockNews.com关于Talaris治疗(TALS)的研究报告
- 新年值得关注的三只医疗保健便士股
- 西南航空公司股票,有很多值得爱的东西
- MarketBeat:回顾一周12/19-12/23
- 这些钢铁制造商理应在2023年观察名单上占有一席之地
- 通胀降温,标普500指数何去何从
Receive News & Ratings for Talaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Talaris治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Talaris治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧